BON Announces The Launch Of Its Postbiotic Hypoglycemic Patented Ingredient Product Series And Its Cooperation Agreement
Bon Natural Life Limited (BON) has announced an exclusive cooperation agreement with Beijing Huahai Keyuan for the distribution of its postbiotic hypoglycemic ingredients. The agreement spans 36 months with a contract value of $32 million. BON's patented product is designed to regulate blood sugar and control post-meal glucose spikes, offering advantages in safety and convenience.
The company is targeting the postprandial blood glucose control market, which has a size of over $30 billion and maintains a 7.5% compound annual growth rate. BON expects significant market advancement and growth in sales and profits over the next 2-3 years through this product line.
Bon Natural Life Limited (BON) ha annunciato un accordo di collaborazione esclusiva con Beijing Huahai Keyuan per la distribuzione dei suoi ingredienti ipoglicemici postbiotici. L'accordo ha una durata di 36 mesi e un valore contrattuale di 32 milioni di dollari. Il prodotto brevettato di BON è studiato per regolare la glicemia e controllare i picchi di glucosio post-prandiali, offrendo vantaggi in termini di sicurezza e praticità.
L'azienda punta al mercato del controllo della glicemia postprandiale, che supera un valore di 30 miliardi di dollari e registra un tasso di crescita annuale composto del 7,5%. BON prevede un significativo progresso di mercato e una crescita di vendite e profitti nei prossimi 2-3 anni grazie a questa linea di prodotti.
Bon Natural Life Limited (BON) ha anunciado un acuerdo exclusivo de cooperación con Beijing Huahai Keyuan para la distribución de sus ingredientes hipoglucemiantes postbióticos. El acuerdo tiene una duración de 36 meses y un valor contractual de 32 millones de dólares. El producto patentado de BON está diseñado para regular el azúcar en sangre y controlar los picos de glucosa después de las comidas, ofreciendo ventajas en seguridad y conveniencia.
La empresa se enfoca en el mercado de control de glucosa postprandial, que supera los 30 mil millones de dólares y mantiene una tasa compuesta anual de crecimiento del 7,5%. BON espera un avance significativo en el mercado y un crecimiento en ventas y beneficios en los próximos 2-3 años mediante esta línea de productos.
Bon Natural Life Limited (BON)은 Beijing Huahai Keyuan과 독점 협력 계약을 체결하여 포스트바이오틱 저혈당 성분을 유통합니다. 계약 기간은 36개월이며 계약 금액은 3,200만 달러입니다. BON의 특허 제품은 혈당 조절과 식후 혈당 급증 억제에 초점을 맞추어 안전성과 편리성을 제공합니다.
회사는 7.5%의 연평균 복합 성장률을 보이는 300억 달러 이상 규모의 식후 혈당 조절 시장을 목표로 하고 있습니다. BON은 이 제품 라인을 통해 향후 2-3년 내에 시장 점유율 확대와 매출 및 이익 증가를 기대하고 있습니다.
Bon Natural Life Limited (BON) a annoncé un accord de coopération exclusif avec Beijing Huahai Keyuan pour la distribution de ses ingrédients postbiotiques hypoglycémiants. L'accord s'étend sur 36 mois avec une valeur contractuelle de 32 millions de dollars. Le produit breveté de BON est conçu pour réguler la glycémie et contrôler les pics de glucose après les repas, offrant des avantages en termes de sécurité et de commodité.
L'entreprise cible le marché du contrôle de la glycémie postprandiale, qui dépasse 30 milliards de dollars et maintient un taux de croissance annuel composé de 7,5%. BON prévoit une avancée significative sur le marché ainsi qu'une croissance des ventes et des bénéfices au cours des 2 à 3 prochaines années grâce à cette gamme de produits.
Bon Natural Life Limited (BON) hat eine exklusive Kooperationsvereinbarung mit Beijing Huahai Keyuan zur Distribution seiner postbiotischen, blutzuckersenkenden Inhaltsstoffe bekannt gegeben. Die Vereinbarung läuft über 36 Monate mit einem Vertragswert von 32 Millionen US-Dollar. Das patentierte Produkt von BON ist darauf ausgelegt, den Blutzuckerspiegel zu regulieren und postprandiale Glukosespitzen zu kontrollieren, wobei Sicherheit und Komfort im Vordergrund stehen.
Das Unternehmen zielt auf den Markt für die Kontrolle des postprandialen Blutzuckers, der über 30 Milliarden US-Dollar umfasst und eine jährliche Wachstumsrate von 7,5% aufweist. BON erwartet in den nächsten 2-3 Jahren durch diese Produktlinie eine deutliche Marktentwicklung sowie Umsatz- und Gewinnsteigerungen.
- Secured a $32 million contract over 36 months with Beijing Huahai Keyuan
- Targeting a large market worth over $30 billion with 7.5% CAGR
- Patented technology for postbiotic hypoglycemic ingredients
- Expected growth in sales and profits over next 2-3 years
- None.
Insights
BON secured a $32M deal for its new postbiotic blood sugar control ingredients in a $30B market growing at 7.5% annually.
BON Natural Life has made a significant business advancement with their 36-month exclusive distribution agreement with Beijing Huahai Keyuan, valued at
The agreement is strategically important as BON aims to penetrate the postprandial blood glucose control market, which currently stands at over
From a technical perspective, BON's patented postbiotic solution appears to offer a differentiated approach to blood sugar management. The company claims their ingredients specifically target post-meal glucose spikes, which is a crucial factor in diabetes management. The emphasis on safety, convenience, and ease of integration into daily routines suggests the product is designed to address key barriers to consistent use in blood sugar control solutions.
The management's stated confidence in establishing a market leadership position suggests they believe their technological approach has meaningful advantages over existing solutions. However, the projected timeline of 2-3 years for "meaningful market advancements" indicates this is a medium-term growth initiative rather than an immediate revenue driver.
This product launch represents a focused expansion of BON's portfolio into a high-growth healthcare segment, potentially creating a significant new revenue stream beyond their existing bio-ingredient business. If successful, this could transform BON from a general natural ingredient provider into a specialized player in the metabolic health space, potentially commanding higher margins and valuation multiples typical of healthcare solution providers.
XI’AN, China, May 16, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced an exclusive cooperation agreement with Beijing Huahai Keyuan (Tech) Co., Ltd., a leading functional ingredient distributor in China. The term of the agreement is 36 months with a total contract value of 32 million US dollars. Pursuant to the agreement, Beijing Huahai Keyuan will serve as the exclusive sales partner of BON’s postbiotic hypoglycemic ingredients. BON aims to expand into the global blood sugar health market through the development of a series of innovative hypoglycemic solutions.
BON’s patented postbiotic hypoglycemic ingredient is designed to regulate blood sugar, delivering targeted control over post-meal glucose spikes and cutting blood sugar surges. It has a high rate of efficacy and also stands out for its safety, convenience, and seamless integration into daily routines-key factors driving high user adherence. We believe with these advantages, the postbiotic hypoglycemic ingredient is poised to revolutionize the postprandial blood sugar control sector and capture significant market share.
Current market data indicates that the postprandial blood glucose control market is a rapidly growing sector, with a market size of over 30 billion US dollars and sustaining a compound annual growth rate of
Drawing on BON's product capabilities and the market strengths of its partners, Hu Yongwei, the Chairman and CEO of BON, remarked: "As the patent holder of postbiotics with groundbreaking technological advantages, we are fully confident in our ability to succeed in the vast and rapidly expanding postprandial blood glucose control market while establishing a leading position. The Company anticipates that its series of hypoglycemic products based on postbiotics will achieve meaningful market advancements over the next 2-3 years, thereby facilitating rapid growth in sales and profits and effectively enhancing the Company's investment value. Meanwhile, the growth of this business line will help accelerate the Company's emergence as a key player in blood glucose health - a critical segment within the broader healthcare sector - while positioning it to become a leader in comprehensive blood glucose health solutions."
About Bon Natural Life Limited ("BON")
BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company's website at http://www.bnlus.com.
For more information, please contact:
Cindy Liu | IR
Email: bonnatural@appchem.cn
Safe Harbor Statement
This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes", "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
_______________________
1. IQVIA "Global Diabetes Treatment Market Outlook 2025
FAQ
What is the value and duration of BON's agreement with Beijing Huahai Keyuan?
What is the market size for postprandial blood glucose control that BON is targeting?
What are the key features of BON's postbiotic hypoglycemic ingredient?
When does BON expect to see significant market advancement from its hypoglycemic products?
